| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000039180 |
| Receipt No. | R000044683 |
| Scientific Title | A study to examine the effects of blood flow improvement and body temperature maintenance effects |
| Date of disclosure of the study information | 2020/02/01 |
| Last modified on | 2020/07/18 (Ver. 2) |
| Basic information | ||
| Public title | A study to examine the effects of blood flow improvement and body temperature maintenance effects | |
| Acronym | A study to examine the effects of blood flow improvement and body temperature maintenance effects | |
| Scientific Title | A study to examine the effects of blood flow improvement and body temperature maintenance effects | |
| Scientific Title:Acronym | A study to examine the effects of blood flow improvement and body temperature maintenance effects | |
| Region |
|
|
| Condition | ||
| Condition | Healthy Individuals | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Clarify that maintaining body-temperature by improving the blood flow of those who are aware of the cold-constitution. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Skin surface temperature |
| Key secondary outcomes | Peripheral blood flow |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -but assessor(s) are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 4 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral intake of the test Food A (Tea) | |
| Interventions/Control_2 | Oral intake of the test Food B (Extract) | |
| Interventions/Control_3 | Oral intake of the test Food C (Tablet) | |
| Interventions/Control_4 | Oral intake of the placebo | |
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | [1]Males and Females aged 20> years.
[2]Those who are conscious of coldness of 4 points or more (Important item; 2 point, Reference item 1 point) in coldness diagnosis questionnaire [3] Those whose skin temperature recovery rate is less than 90% after 10 minutes of cold load in skin temperature recovery rate measurement [4] Those who obtain consent from the document with free will of the subject |
|||
| Key exclusion criteria | [1]Those who are at risk of developing allergy in connection with research
[2]Those who have been diagnosed as underlying diseases associated with vascular disorders (obstructive arteriosclerosis, obstructive arteritis, collagen disease, diabetes etc.) [3]Those who were judged inappropriate as subjects from the answers to the questionnaire [4]Those who have a smoking habit [5]Those who regularly use prescribed medicines (eg, warfarin, etc.) that may affect blood flow and skin surface temperature [6]Those who take foods for specified health use or health foods that affect blood flow and skin surface temperature for three days or more per week [7]Those already taking citrus drinks such as shikuwasa and oranges more than 3 days a week [8]Those who were judged to have problems with research participation due to abnormalities in clinical laboratory values or cardiorespiratory functions [9]Those who have a disease requiring continuous medication, those who have had a serious medical history requiring medication therapy [10]Persons whose values of physical measurement values, physical examination values and clinical laboratory values before the start of ingestion are significantly deviated from the reference range [11]Those who participate in other clinical research at the start of this research [12]Others who judged that the researcher is inappropriate as the subject |
|||
| Target sample size | 36 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Medicial Corporation Kenshokai | ||||||
| Division name | Fukushima Healthcare Center | ||||||
| Zip code | 553-0004 | ||||||
| Address | Tamagawa 2-12-16, Fukushima-ku, Osaka-shi, Osaka, 553-0004, Japan | ||||||
| TEL | 06-6441-6848 | ||||||
| rtakeda@tamateyama.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Kansai University of Welfare Sciences | ||||||
| Division name | Department of Nutritional Sciences for Well-being | ||||||
| Zip code | 582-0026 | ||||||
| Address | Asahigaoka 3-11-1, Kashiwara-cuty | ||||||
| TEL | 072-978-0088 | ||||||
| Homepage URL | |||||||
| rtakeda@tamateyama.ac.jp | |||||||
| Sponsor | |
| Institute | Medicial Corporation Kenshokai, Fukushima Healthcare Center |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Musashino Rsearch Institute for Immunity Co., Ltd |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Brain Care Clinic Ethics Review Committee |
| Address | Samon-Cho13, Isobe Build. 2F, Shinjyuku-ku, Tokyo |
| Tel | 03-3351-3386 |
| yuyosei@drc-web.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000044683 |